Watch this space for our coverage of systemic lupus erythematosus (SLE) sessions at ACR Convergence 2020, beginning with a report on the State of the Art: Lupus—the Future Is Now session, moderated by Saira Sheikh, MD. Plus, explore our collection of research reviews, case reports and clinical articles on advances in the diagnosis and management of SLE.
With funding support from the CDC, in this ACR initiative, rheumatology fellows in training deliver lupus education sessions to medical personnel & rheumatologists connect with medical colleagues in underserved rural areas.
Research demonstrating the effectiveness of subcutaneous anifrolumab-fnia as an auto-injector in patients with active systemic lupus erythematosus is the basis of a recent decision in the EU to recommend the treatments approval for this patient population.
Experts discussed how aspects of the immune system other than B cells play a role in lupus, including mitochondria in red blood cells, proteins present in urine and more.
This review highlights some of the many abstracts on lupus nephritis research presented at ACR Convergence 2025. They demonstrate advances made on early recognition of the condition, as well as offering some hope in terms of achieving better outcomes.
At the Dubois Memorial Lecture presented at ACR Convergence 2025, Shaun Jackson, MD, PhD, discussed the evolving understanding of the role of B cells in SLE.
Urine biomarkers have the potential to change how lupus nephritis is managed, serving as a noninvasive means of early detection, assessing treatment response and more.